Last Updated: February, 2026
Trusted by 200+ Clients
Compare & Choose the Right Report Version for You
How to Order Your Report?
The report provides a detailed analysis essential for establishing a pemigatinib production plant. It encompasses all critical aspects necessary for pemigatinib production, including the cost of pemigatinib production, pemigatinib plant cost, pemigatinib production costs, and the overall pemigatinib production plant cost.
Additionally, the study covers specific expenditures associated with setting up and operating a pemigatinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Pemigatinib is a targeted medicine that blocks certain proteins called FGFR1, FGFR2, and FGFR3, which can fuel cancer growth. It mainly treats bile duct cancer (cholangiocarcinoma) in adults that has spread or cannot be removed by surgery. It binds to these receptors, blocking unusual signalling that promotes uncontrolled cancer cell proliferation, survival, angiogenesis, and metastasis in tumours with FGFR fusions, mutations, or amplifications. It is FDA-approved for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma. It delivers durable responses and extended progression-free survival. Its side effects include ocular toxicity, hyperphosphatemia, and fatigue, which require vigilant monitoring.
The market for pemigatinib is driven by the rising incidence of cholangiocarcinoma and other FGFR-altered cancers. The advanced diagnostics that identify suitable patients through companion tests contribute to its market growth. Innovations in precision medicine, expanding clinical trials for new tumour types (e.g., bladder, pancreatic), regulatory approvals, and investments in developing markets boost its demand.
The industrial pemigatinib procurement is driven by high costs as an oral targeted therapy, reimbursement negotiations, and patient assistance programs. Other factors like supply chain stability, regional healthcare budgets, and competition from other FGFR inhibitors like futibatinib or erdafitinib impact its sourcing strategies.
According to the pemigatinib production plant project report, the key raw materials used in the production of pemigatinib include pyrrolopyridine and mesyl chloride.
The extensive pemigatinib production cost report consists of the following major industrial production process:
Pemigatinib is a small-molecule kinase inhibitor that has the molecular formula of C24H27F2N5O4 with a molecular weight of 487.5 g/mol. It has a complex tricyclic pyrrolopyridopyrimidinone core featuring a 2,6-difluoro-3,5-dimethoxyphenyl substituent, an ethyl group at N1, and a 4-morpholinylmethyl side chain at C8. It appears as a white to off-white crystalline powder, practically insoluble in water but soluble in DMSO and organic solvents. It has a melting point around 220-230 degree Celsius with a logP value of 3.5, indicating moderate lipophilicity. Its pKa values make it suitable for oral absorption (basic nitrogen ~6.5) and high plasma protein binding (~90%). It is stable under physiological conditions but susceptible to CYP3A4 metabolism. Its formulation includes lactose monohydrate, microcrystalline cellulose, and croscarmellose sodium excipients, with bioavailability ~80% under fed conditions.
Pemigatinib Production Cost Report
Choose What's Right for You
Pay Via
| Particulars | Details |
|---|---|
| Product Name | Pemigatinib |
| Scope | Production Process: Process Flow, Material Flow, Material Balance Raw Material and Product Specifications: Raw Material Consumption, Product and Co-product Generation Land and Site Cost: Offsites/Civil Works, Equipment Cost, Auxiliary Equipment Costs, Contingency, Engineering and Consulting Charges, Working Capital Variable Cost: Raw Material, Utilities, Other Variable Costs Fixed Cost: Labor Requirements and Wages, Overhead Expenses, Maintenance Charges, Other Fixed Costs Financing Costs: Interest on Working Capital, Interest on Loans Other Costs: Depreciation Charges, General Sales and Admin Cost |
| Currency | US$ (Data can also be provided in the local currency) |
| Pricing and Purchase Options | Basic: US$ 2499 Premium: US$ 3499 Enterprise: US$ 4799 |
| Customization Scope | The report can be customized as per the requirement of the customer |
| Post-Sale Analysts Report | 10-12 weeks of post-purchase analyst support after report delivery for any queries from the deliverable |
| Delivery Format | PDF and Excel format through email (editable version in PPT/Word format of the report can be also provided on special request) |
At Procurement Resource, we not only focus on optimizing the should cost of production for pemigatinib but also provide our clients with extensive intel and rigorous information on every aspect of the production process. By utilizing a comprehensive cost model, we help you break down expenses related to raw materials, labor, and technology, offering clear pathways to savings. We also assist in evaluating the capital expenditure (CAPEX) and operating expenses (OPEX), which are often measured as cost per unit of production, such as USD/MT, ensuring that your financial planning is aligned with industry benchmarks.
We offer valuable insights on the top technology providers, in-depth supplier database, and best manufacturers, helping you make informed decisions to improve efficiency. Additionally, we design the most feasible layout for your production needs, ensuring the entire process runs smoothly. By minimizing the cash cost of production, we ensure that you stay competitive while securing long-term profitability in the growing pemigatinib market. Partnering with Procurement Resource guarantees that every aspect of your production is cost-efficient, advanced, and tailored to your specific requirements.
Vishakha Agrawal
Lead - Social & Development Research
Delivering procurement intelligence and supply chain analytics across healthcare, FMCG, and chemicals sectors, with expertise in cost modeling, vendor mapping, and spend optimization to support data-driven sourcing decisions and procurement outcomes.
Need more help?
Still Need Help?
